Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 79.00 | |
5 mg | In stock | $ 239.00 | |
10 mg | In stock | $ 363.00 | |
25 mg | In stock | $ 613.00 | |
50 mg | In stock | $ 873.00 | |
100 mg | In stock | $ 1,180.00 | |
500 mg | In stock | $ 2,380.00 |
Description | RO9021 is an orally bioavailable, novel ATP-competitive SYK inhibitor (average IC50: 5.6 nM). |
Targets&IC50 | Syk:5.6 nM |
In vitro | RO9021 effectively inhibits the anti-IgM induced phosphorylation of key signaling proteins including BTK, PLCγ2, AKT, and ERK, thereby demonstrating its capacity to block SYK kinase activity and consequently attenuate the B-cell receptor (BCR) downstream signaling cascade. This compound selectively targets B-cell receptor signaling, underscored by its role as a highly selective inhibitor of SYK. Its selectivity is evidenced by low S-scores of 0.003 for S(99) and 0.015 for S(90), indicating that among 392 kinases tested, SYK is the sole kinase significantly competed by RO9021 with 99% effectiveness. Moreover, RO9021 exhibits comparable inhibitory potency (IC50=22.8±1.7 nM) in assays measuring FcεR-mediated mast cell activation and degranulation, highlighting its broad potential in modulating immune responses [1]. |
Molecular Weight | 355.44 |
Formula | C18H25N7O |
CAS No. | 1446790-62-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3 mg/mL (8.44 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RO9021 1446790-62-0 Angiogenesis Tyrosine Kinase/Adaptors Syk Spleen tyrosine kinase Inhibitor RO 9021 inhibit RO-9021 inhibitor